Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.73 |
| ▸ | PGR | P06401 | 8/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 9/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010556 | 0.82 | NR3C1 (0.49) | NR3C1PGRNR3C2TP53 | |
| SCHEMBL2006759 | 0.77 | NR3C1 (0.55) | NR3C1PGRNR3C2BRD4BRD2 | |
| SCHEMBL2005877 | 0.69 | TAAR1 (0.41) | — | |
| SCHEMBL16046785 | 0.68 | NR3C1 (0.53) | NR3C1PGRNR3C2BRD4BRD2 | |
| SCHEMBL29411654 | 0.66 | NR3C1 (0.57) | NR3C1PGRNR3C2BRD4BRD2 | |
| SCHEMBL21045494 | 0.66 | NR3C1 (0.57) | NR3C1PGRNR3C2BRD4BRD2 | |
| SCHEMBL5080200 | 0.65 | NR3C2 (0.64) | NR3C1PGRNR3C2 | |
| SCHEMBL5607587 | 0.65 | NR3C2 (0.64) | NR3C1PGRNR3C2 | |
| SCHEMBL14278643 | 0.65 | NR3C2 (0.57) | NR3C1PGRNR3C2BRD4BRD2 | |
| SCHEMBL17802626 | 0.65 | LMNA (0.53) | NR3C1PGRBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 131/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.